PF-08046050
- Generic Name
- PF-08046050
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell LungStomach NeoplasmsSmall Cell Lung CarcinomaGastroesophageal Junction AdenocarcinomaColorectal NeoplasmsPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 494
- Registration Number
- NCT06131840
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath